Petros Pharmaceuticals Net Worth
Petros Pharmaceuticals Net Worth Breakdown | PTPI |
Petros Pharmaceuticals Net Worth Analysis
Petros Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Petros Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Petros Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Petros Pharmaceuticals' net worth analysis. One common approach is to calculate Petros Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Petros Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Petros Pharmaceuticals' net worth. This approach calculates the present value of Petros Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Petros Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Petros Pharmaceuticals' net worth. This involves comparing Petros Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Petros Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Petros Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Petros Pharmaceuticals' net worth research are outlined below:
| Petros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Petros Pharmaceuticals has high historical volatility and very poor performance | |
| Petros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Petros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.82 M. Net Loss for the year was (8.16 M) with profit before overhead, payroll, taxes, and interest of 6.21 M. | |
| Petros Pharmaceuticals currently holds about 13.3 M in cash with (7.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3 |
Petros Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Petros Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Petros Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Petros Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Petros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Petros Pharmaceuticals backward and forwards among themselves. Petros Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Petros Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Fidelity Management And Research Company | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Newbridge Financial Services Group, Inc. | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 70.3 K | Two Sigma Securities, Llc | 2024-06-30 | 53.9 K | Geode Capital Management, Llc | 2024-09-30 | 37.5 K | Vanguard Group Inc | 2024-09-30 | 31.8 K | Blackrock Inc | 2024-06-30 | 16.5 K | Tower Research Capital Llc | 2024-06-30 | 3.3 K |
Follow Petros Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.71 M.Market Cap |
|
Project Petros Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.65) | (0.62) |
When accessing Petros Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Petros Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Petros Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Petros Pharmaceuticals' management efficiency
Petros Pharmaceuticals has return on total asset (ROA) of (0.3061) % which means that it has lost $0.3061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6377) %, meaning that it created substantial loss on money invested by shareholders. Petros Pharmaceuticals' management efficiency ratios could be used to measure how well Petros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.35. The current Return On Capital Employed is estimated to decrease to -0.62. As of now, Petros Pharmaceuticals' Non Current Assets Total are decreasing as compared to previous years. The Petros Pharmaceuticals' current Non Currrent Assets Other is estimated to increase to about 6.2 M, while Other Assets are projected to decrease to under 9.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.74 | 5.45 | |
| Tangible Book Value Per Share | 1.61 | 1.69 | |
| Enterprise Value Over EBITDA | 0.47 | 0.45 | |
| Price Book Value Ratio | 0.25 | 0.33 | |
| Enterprise Value Multiple | 0.47 | 0.45 | |
| Price Fair Value | 0.25 | 0.33 | |
| Enterprise Value | -2 M | -1.9 M |
Effective leadership at Petros Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 6.6519 | Revenue 4.1 M | Quarterly Revenue Growth (0.29) | Revenue Per Share 0.99 | Return On Equity (0.64) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Petros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Petros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Petros Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gesek Andrew over a week ago Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3 | ||
John Shulman over two weeks ago Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3 | ||
John Shulman over a month ago Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3 | ||
Silverman Joshua over two months ago Insider Trading | ||
Bradley Greg over six months ago Acquisition by Bradley Greg of 22642 shares of Petros Pharmaceuticals subject to Rule 16b-3 | ||
Bernstein Bruce over a year ago Exercise or conversion by Bernstein Bruce of 6050 shares of Petros Pharmaceuticals subject to Rule 16b-3 | ||
Bernstein Bruce over a year ago Acquisition by Bernstein Bruce of 000 shares of Petros Pharmaceuticals subject to Rule 16b-3 |
Petros Pharmaceuticals Earnings per Share Projection vs Actual
Petros Pharmaceuticals Corporate Management
| Mitchell MBA | VP Officer | Profile | |
| Keith Lavan | Advisor | Profile | |
| John Shulman | Executive Board | Profile | |
| Robert Weinstein | Interim Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.84) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.